To comprehensively evaluate the association between postdiagnostic statin use and mortality of ovarian cancer (OC) patients.
Introduction
Epithelial ovarian cancer (OC) has the highest death rate among all gynaecological malignancies worldwide and accounts for the majority of gynaecological cancer-related deaths with an estimated 14 080 deaths in the USA in 2017 [1] . Attributed to presentation at a late stage of disease and a lack of specific symptoms, half of these patients experience recurrence within 16 months and the 5-year overall survival (OS) rate is only 35-40% [2] [3] [4] . Therefore, the development of strategies to improve the prognosis of OC will have great implications in treatment outcomes.
Statins are widely used among US adults to lower lowdensity lipoprotein cholesterol levels and prevent cardiovascular disease, as approximately 28% of the population aged >40 years reportedly used statins in 2012 [5] . Statins inhibit the rate-limiting step in cholesterol biosynthesis and block protein prenylation, which has been associated with several potential anticancer properties and a reduced risk of cancer recurrence by lowering serum cholesterol levels, as well as influencing cell proliferation and migration [6] [7] [8] [9] [10] [11] . Numerous experimental studies have suggested that statins may exert antineoplastic effects through induction of apoptosis and suppression of tumour growth, angiogenesis and metastasis [9] [10] [11] . Although these potential biological mechanisms appear promising, findings from cell and animal studies cannot be extrapolated in humans for several reasons, especially metabolic differences between humans and other species [12, 13] .
Recent epidemiological evidence on the association between postdiagnostic statin use and the survival of OC patients are sparse and controversial. In a systematic review and meta-analysis up to April 2015, Zhong et al. [14] examined the effect of statin use on the mortality of all cancers, but only included three studies [15] [16] [17] that investigated the correlation between postdiagnostic statin use and mortality of OC patients. However, in view of this metaanalysis, several relevant high-quality studies with large sample sizes have been published [18] [19] [20] [21] [22] , with some suggesting that postdiagnostic statin use was associated with decreased mortality of OC [18, 19] , while others [20] [21] [22] failed to find any evidence of such an association. Since reviewing the available evidence may provide insight for further research to understand the potential role of statin use in OC therapy, the aim of the present systematic review and meta-analysis of observational studies was to assess the effect of postdiagnostic statin use on the mortality/survival of OC patients.
Methods

Data sources and searches
The present systematic review and meta-analysis was performed in accordance with the recommendations of the Meta-Analysis of Observational Studies in Epidemiology group [23] In addition, the reference lists of published narrative reviews were scanned to identify potential additional publications not retrieved by the manual search [24, 25] . In an effort to identify unpublished studies, the abstracts of the annual meetings up to 31 December 2017 of the related associations were also manually searched.
Study selection
NoteExpress Research & Reference Manager software (version 3.0; Aegean Software, Beijing, China) was used to identify and remove duplicate records. Subsequently, two individuals independently scanned each title and abstract. The full text of all studies that advanced beyond this stage were independently reviewed. Once a consensus was reached, the studies that fulfilled the following criteria were included for the meta-analysis: (i) a cohort study or randomized controlled trial; (ii) assessed the relationship of postdiagnostic statin use with survival/mortality of OC patients; and (iii) included hazard ratios (HRs) or relative risk analyses with 95% confidence intervals (CIs), or provided data allowing the calculation of the risk estimates and 95% CIs. Ecological studies, case-control studies, reviews without original data, editorials, commentaries, meeting abstracts and case reports, as well as studies that investigated the association between prediagnostic statin use with survival/mortality of OC patients, and those that reported risk estimates without 95% CIs (e.g. studies that could not be included in the statistical summary) were excluded from analysis. 
Data abstraction
Risk of bias assessment of individual studies
To assess the risk of bias of the included studies, two individuals independently used the Newcastle-Ottawa quality assessment scale for cohort studies [26] [27] [28] [29] [30] relying only on the information presented in the reports and making no assumptions. Any disagreements were referred to a third team member. The Newcastle-Ottawa quality assessment scale uses the three quality parameters of selection, comparability, and exposure/outcome assessment. Subsequently, studies that achieved a full rating in at least two categories of these three assessments were considered to have a low risk of bias [28, 31] .
Statistical analysis
For one study [21] that did not use the category of never use as a reference to statin use, the effective-count method proposed by Hamling et al. [32] was used to recalculate the HRs and 95% CIs. Overall summary estimates were calculated using inverse variance-weighted random effects metaanalysis. Individual HR and summary estimates are displayed graphically as forest plots. Heterogeneity across the studies was quantified using the I 2 statistic, which estimates the proportion of variability in the meta-analysis caused by differences between studies rather than sampling error [33] . The cut-off points of <30%, 30-50% and >50% were used to indicate low, moderate and substantial levels of heterogeneity. Furthermore, the sequential exclusion strategy proposed by Patsopoulos et al. [34] was used to examine whether the overall estimates were influenced by the substantial heterogeneity observed. Based on a priori decisions, subgroup analyses for OS/ACM was conducted according to the geographical location (Europe, America and Asia), study quality (low vs. high risk), median number of OC cases (≥ 1000 vs. < 1000), type of cohort (retrospective vs. prospective), FIGO stage (all vs. III-IV), histological type (serous, mucinous, endemetrioid and clear cell), source of exposure (prescription database vs. medical records), statistical analysis (time-dependent vs. not timedependent), and adjustments made for potential confounders (including age at diagnosis, FIGO stage, grade, comorbidity, residual disease, chemotherapy and nonstatins drug use).
The possibility of small study biases (e.g. publication bias) was explored visually, checking for asymmetry in contoured funnel plots of treatment effects against individual standard errors using formal statistical procedures. Specifically, the Begg et al. [35] and Egger et al. [36] methods were applied to examine possible effects of the inclusion of small studies. The trim-and-fill method was used to reduce the potential influence of publication bias [37] .
A series of sensitivity analyses were performed to better understand the sources of statistical heterogeneity between studies, as well as to test the robustness of the findings. First, to examine the effect of individual studies on the summary estimates, influence analysis was conducted, in which the pooled estimates were recalculated by omitting one study at a time. Second, meta-regression analysis was used to assess differences between subgroups. A P value of <0.05 was considered statistically significant. All statistical analyses were performed using Stata 12.0 software (Stata LLC, College Station, TX, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [38] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [39] .
Results
Search results, study characteristics and quality assessment
The search strategy generated 269 articles, of which 12 were considered of potential value, thus the full texts of these articles were retrieved for detailed evaluation (Figure 1 ). Four [40] [41] [42] [43] of these 12 articles were subsequently excluded for various reasons and a review of the reference lists led to the inclusion of one additional article. Therefore, eight studies [15] [16] [17] [18] [19] [20] [21] [22] were included in the present meta-analysis. Table 1 shows the key characteristics of the included studies, which were published from 2008 to 2017 and included a total of 19 904 OC patients with a range of 60-8159 cases per study. The proportion of patients on statins ranged from 11% to 42.6%. Three of the included studies were conducted in Asia [15, 21, 22] , three in Europe [16, 18, 20] and two in America [17, 19] . Most of the cohort studies were retrospective [15, 17-19, 21, 22] , while two were prospective [16, 20] . The median duration of followup varied across studies from 28.8 to 54 months and the rate of statin use ranged from 11% to 42.6%. Table 2 demonstrates the adjustment for confounders in the primary analysis of these included studies, all of which were adjusted for age at diagnosis. The majority of studies were adjusted for FIGO stage (n = 7), comorbidity (n = 5), and chemotherapy (n = 5). However, few studies were adjusted for tumour grade (n = 2), residual disease (n = 2) nonstatin drug use (n = 2). Of note, none of the included studies were adjusted for performance status (n = 0).
Figure 1
Selection of studies for inclusion in the present meta-analysis Table 1 Characteristics of included studies Study quality scores are summarized in Table 3 . Six studies [15, 16, [18] [19] [20] 22] were graded as low risk and two [17, 21] as high risk. The most common selection bias was related to the representativeness of the exposed cohort and selection of the unexposed cohort, the most comparability bias was the control for important factor or additional factor, and the most common outcome bias was a sufficient duration of followup for outcomes to occur (Table 3) .
Postdiagnostic statin use and ACM of OC patients (user vs. nonuser)
Seven studies [15, [17] [18] [19] [20] [21] [22] involving 11 745 subjects with OC were used to estimate the summary effects of postdiagnostic statin use on ACM. The summarized HR was 0.74 (95%CI = 0.63-0.87), with moderate heterogeneity (I 2 = 55%, P = 0.038) (Figure 2 ). Publication bias was not detected by the Begg's (P = 0.23) and Egger's tests (P = 0.16), and visual inspection of the funnel plot indicated symmetry. When one study [19] that contributed the largest amount to heterogeneity until I 2 was <50% was sequentially excluded, the summarized outcomes (HR = 0.82, 95%CI = 0.76-0.90, I 2 = 45.6%) were similar to the main results. Additionally, sensitivity analyses showed that no study was influential, when one study at a time was omitted. A pooled HR was calculated for the remainder of the studies (Figure 3) . The estimated HR in this sensitivity analysis Table 4 presents the results of subgroup analyses. Notably, the majority of these findings were statistically significant as well as consistent with the main result. More specifically, significant results of subgroup analysis stratified by histology were only observed in patients with serous OC. Metaregression analyses in consideration of the potential variables mentioned showed no effect of modifiers.
Intensity of postdiagnostic statin use and ACM of OC patients (highest vs. lowest)
For three studies [18] [19] [20] involving 11 266 OC cases that investigated the intensity of postdiagnostic statin use and ACM, the summarized HR was 0.84 (95%CI = 0.74-0.96) without heterogeneity (I 2 = 0%, P = 0.444) (Figure 4 ).
Postdiagnostic statin use and secondary outcomes of OC patients (user vs. nonuser)
Three studies [15, [17] [18] [19] [20] [21] [22] were used to estimate the summary effects of postdiagnostic statin use on cancer-specific mortality and one [20] 
FIGO, International Federation of Gynecology and Obstetrics; PS, performance status. Table 3 Methodological quality of included studies A cohort study with a median follow-up time ≥ 24 months was assigned one star.
c A cohort study with a follow-up rate > 75% was assigned one star.
Discussion
This systematic review and meta-analysis, based on eight relevant studies that together included 19 904 patients with OC, provides significant evidence of an overall protective effect of postdiagnostic statin use on ACM and cancer-specific mortality. The potential biological mechanisms by which postdiagnostic statin use may improve the survival of OC patients have been investigated in previous studies.
Experimental studies have demonstrated that statins exert antineoplastic effects not only through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductasedependent pathways, but also those that are independent of HMG-CoA reductase. By competitive inhibition of HMGCoA reductase, blocking the conversion of HMG-CoA into mevalonate, statins can reduce synthesis of the mevalonic acid pathway intermediates, which modify and activate proteins, such as small signalling G proteins of the Ras/Rho superfamily, involved in the onset and progression of cancer [19, [44] [45] [46] . By contrast, this class of drug also exerts proapoptotic effects through regulation of the RAF/mitogenactivated protein kinase 1/extracellular signal-regulated kinase pathway through an HMG-CoA reductase-dependent mechanism by activating caspases and decreasing Bcl-2 [47] [48] [49] . Statins inhibit activation of the proteasome pathway, thereby limiting the breakdown of the cyclindependent kinase inhibitors p21 and p27, and allowing these molecules to exert their growth-inhibitory effects [50] . Furthermore, by modifying the cell adhesion cascade through the aforementioned pathways, statins exert both anti-inflammatory and immunomodulatory effects [51] .
In the subgroup analysis stratified by histology, only postdiagnostic statin use was significantly associated with ACM among patients with serous OC. Although the possibility of chance findings could not be ruled out, these results were inconsistent with the findings of several previous studies. For example, Habis et al. [41] reported a substantial reduction in mortality with statin use among nonserous OC patients with hyperlipidaemia, whereas no association was observed for those with OC and normal lipid levels overall. Additionally, similar phenomena among patients with endometrioid or clear cell OC were reported by Verdoodt et al. [20] . Given that OC is Figure 2 Forest plot (random-effects model) of postdiagnostic statin use and all-cause mortality/overall survival of epithelial ovarian cancer patients (user vs. nonuser). The squares indicate study-specific HR (size of the square reflects the study-specific statistical weight); the horizontal lines indicate 95%CIs; and the diamond indicates the summary HR estimate with its 95%CI. CI, confidence interval; HR, hazard ratio Figure 3 Sensitivity plot corresponding to the relationship between postdiagnostic statin use and all-cause mortality/overall survival of epithelial ovarian cancer patients. The circles indicate study-specific hazard ratio after excluding the present study; the horizontal dotted lines indicate 95% confidence intervals Table 4 Risk estimate summary of the association of postdiagnostic statin use and mortality of ovarian cancer patients (user vs. nonuser) heterogeneous and different histological subtypes exhibit different clinical profiles [52] , the protective effects of statins could be limited to specific disease subtypes. Hence, more studies are needed to better evaluate the potential heterogeneity of the effect of statin use with histological subtypes of OC [20] . a Studies that achieved a full rating in at least two categories of these three assessments were considered to have a low risk of bias.
*P-value for heterogeneity within each subgroup. **P-value for heterogeneity between subgroups in meta-regression analysis.
Figure 4
Forest plot (random-effects model) of intensity of postdiagnostic statin use and all-cause mortality/overall survival of epithelial ovarian cancer patients (highest vs. lowest). The squares indicate study-specific HR (size of the square reflects the study-specific statistical weight); the horizontal lines indicate 95%CIs; and the diamond indicates the summary HR estimate with its 95%CI. CI, confidence interval; HR, hazard ratio
This study had several strengths. To the best of our knowledge, this is the most comprehensive meta-analysis to combine available published studies on statin use and survival following OC diagnosis. As compared with the meta-analysis conducted by Zhong et al. [14] (n = 8435), the present analysis included five additional studies comprising 11 469 OC patients. Additionally, this study also investigated the intensity of postdiagnostic statin use and mortality of OC, unlike previous reports. By combining these studies, the statistical power had increased, which allowed detection of weaker associations than in the individual studies. Notably, the results of these numerous preplanned subgroup and sensitivity analyses were consistent, which suggested that the results were robust.
Besides these previously described strengths in the present analysis, there were several limitations that merit further discussion. First, except for two studies conducted in Denmark [16, 20] , the majority of the included studies (n = 6) were retrospective chart reviews, which may bear potential risks of selection and information biases, even though the data were obtained from medical records. Furthermore, to a large extent, as compared to medical records, the use of a prescription database could track use of statins and the majority of nonstatin drugs during the entire study period. Of note, modelling statin as a time-dependent variable in the Cox regression analysis could remove immortal time bias due to the added time between surgery and the initiation of statin treatment [19, 53] . Although the results of the metaregression analysis failed to show statistical significance when stratified by the source of exposure, the results were consistent with the data in the prescription database when treating statin use as a time-dependent variable with the main finding. Second, there was no information on the compliance to the use of statins and other drugs among OC patients. Although a study conducted in Denmark reported that the general compliance to statin therapy was high (>80%) [54, 55] , no evaluation has been performed specifically for OC patients. Third, due to the characteristics of observational studies, the possibility of residual confounding from unmeasured or incomplete variables could not be ruled out. Postdiagnostic statin use is typically associated with various clinical and nonclinical characteristics, such as age, comorbidity (e.g. ischaemic heart disease), performance status, chemotherapy and nonstatin drug use. However, not all of these studies were adjusted for these potential confounders. Although these potential confounders were not sources of heterogeneity in the present study, as suggested by the results of the meta-regression analysis, slightly different point estimates were observed by subgroup analyses, which might be partly attributed to the limited number of studies. Interestingly, an in vitro study demonstrated that statins exhibit cytotoxic synergy with platinum treatment [56] . Although a relatively weaker association was observed in studies adjusted for chemotherapy, none had conducted subgroup analysis to test this hypothesis. Therefore, further studies stratified by additional risk factors are needed to better rule out the potential effects of residual confounders. Fourth, only one of the included studies conducted separate analyses by statin type and solubility, which found a significantly protective effect of hydrophilic rosuvastatin and lipophilic simvastatin. Since in vivo studies suggested that rosuvastatin and fluvastatin were the most potent compounds in animal models [57, 58] , future epidemiological studies are needed to investigate this issue further.
In summary, the present systematic review and metaanalysis demonstrated evidence of a significant protective effect of postdiagnostic statin use on OS and cancer-specific survival. Importantly, increased intensity of statin use was
Figure 5
Forest plot (random-effects model) of postdiagnostic statin use and cancer-specific mortality of epithelial ovarian cancer patients (user vs. nonuser). The squares indicate study-specific HR (size of the square reflects the study-specific statistical weight); the horizontal lines indicate 95%CIs; and the diamond indicates the summary HR estimate with its 95%CI. CI, confidence interval; HR, hazard ratio significantly associated with improved OS. Further prospective cohort or randomized controlled trials are warranted to confirm the therapeutic role of statins in OC.
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